# AbbVie: Phase 1 study started recruiting, 130 planned (Advanced Solid Tumors, Non-Small Cell Lung Cancer)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | AbbVie |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors |
| NCT ID | NCT07807956 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Advanced Solid Tumors; Non-Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma |
| Intervention types | drug |
| Target enrollment | 130 |
| Site countries | United States |
| Posted | 2026-09-08 |
| Planned start | 2026-09-14 |
| Event | Started recruiting |
| Event date | 2026-09-14 |
| Last update posted | 2026-10-16 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- 130 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07807956). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.